RE: Way under value stock My target 10p+ imo Dyor27 Apr 2020 10:40
Mine 15p then the afterburners will kick in, many II's and asset management etc, have a floor of £50M market cap on a company before it meets their investment criteria. NCYT hit that mark at 86p then kicked off rapidly to £2 and the rest is history
Make no mistake if they develop the covid antibody CURE they call it treatment but if you inject something into an already infected patient that attacks and kills the virus is that not a CURE
Tests will never stop you getting sick or fix you, the lung treatments tils/sng are to help you breath while your immune system fights back (creating antibodies)
If Hemo can produce antibodies to inject directly, it would be priceless and save many many lives
Absolutely, as they say most will only have milder symptoms but if your one of those that gets worse symptoms, you would like to think, something down in that icu that will give you a fighting chance not the current 50/50 Outside of that, the antibodies can be injected earlier to stop people getting to that horror stage
RE: Another drug fails in the covid fight....24 Apr 2020 17:25
Hemo's approach is brilliant if successful, it will be like getting a working vaccine immediately if infected as antibodies injected will go straight for the virus Better and quicker than the vaccine, which relies on fooling the immune system to provoke a reaction and then creates the antibodies So something that can attack the virus until such time as an easily available worldwide vaccine comes into play. GLA
can't rely on any on these sites, as soon as share gets busy the dumb arse machine that decides if it was buy or sell or even unknown on the mid, turns rabbit In the headlights and does not keep up with what is actually happening with live trades and the range of prices available, its only ever generic at best, when MM's compete some are buying above mid others selling below so all mislabelled by crap machine basing all on what it thinks is the mid
That's exactly what it would be, same principal as all vaccines harmless version identifies markers the immune system will target and creates antibodies as if you have the disease to prevent you getting in the future, in this case Hemo treatment would skip that creation in the body step and put ready made antibodies into the patient to kick covid's arse Potentially the biggest of all the covid plays tests never stop you getting the disease or fix you if you do, the lung treatments will only help if given soon enough to rebalance the body so the immune system kills it before you go into organ failure. This will be in effect sending in the good guys to attack it. Good luck to us all, could be one hell of a ride.
Welcome aboard Solstace the antibody treatment could be massive but hemo was already way undervalued from its other projects which include a proved to be effective lukemia treatment should be much higher on that alone
Just the usual dumb machine which adds all the data after the trade volume amount and many are from yesterday. On the market they are just trades, it adds the rest and is always bloody useless on busy shares. Will only see what's really going on and the range of prices available if watching a live trade platform.
Without tracking back initially looks like 3 buys and 2 sells, as 2 sets are close to each other with price differences suggesting each pair a buy and sell.
Guesswork but hoping all where actually sells and we are clear to rise in the morning can but wish lol
GDR was sub 10 when it was tipped on twitter, HEMO just following the same pattern as the rest all have been slow burners initially clearing legacy funders overhangs or distressed seller's then turning on afterburners into multi baggers and then some.
Think your probably right it was certainly in the billions but the old noggin cant remember the figure, he has announced quite a few in the past month , all with huge pots of money
yes, not sure of the amount but it had an added bonus, all of the loan would be written off, if the funding proved to be used for COVID developments only. If used to keep company afloat and also spent on existing non related projects would have to pay back at low interest rates, if its the same one I read recently.
Drop symptomatic of the whole pharm sector in London, some like Summit have already binned London in favour of a USA listing as sector far better supported, one of the current covids TILS was due to bin AIM in Q2 having now listed on the Nasdaq TLSA HEMO like many other squeezed pharm shares now back in vogue due to this outbreak, leading Governments will not want a repeat, so funding for research and development, should no longer be an issue for the sector.
On the market ALL are just trades on sites a dumb arse machine adds the rest of the data based on what it sees as the mid, when a share gets busy and MM's compete for custom some will be buying above that mid and others may be selling below. It fails miserably to keep up with the range of prices available and as long as what it sees are trades within its full range bid/mid/ask it does not change hence times only active mm's all below the mid so all appear sells similarly if remaining active mm's all working above perceived mid all appear buys Can blame MM's for many things but all this type stuff is the dumb machine not them to the point where it goes tilt if trade on exactly the mid it labels ffs UNKNOWN